Log In
Print this Print this

molindone (SPN-810)

  Manage Alerts
Collapse Summary General Information
Company Supernus Pharmaceuticals Inc.
DescriptionExtended-release formulation of molindone, an antipsychotic
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationAttention deficit hyperactivity disorder (ADHD)
Indication DetailsTreat impulsive aggression in patients with ADHD; Treat impulsive aggression in pediatric patients with ADHD
Regulatory Designation U.S. - Fast Track (Treat impulsive aggression in patients with ADHD)

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today